Intensity Therapeutics, Inc.
8 Wright Street
Suite 107
Westport
Connecticut
06880
United States
Tel: 203-682-2434
Fax: 203-664-1051
About Intensity Therapeutics, Inc.
Intensity Therapeutics is a biotechnology company whose mission is to greatly extend the lives of cancer patients. Late stage solid cancer consists of well-defined visible tumors and unseen micro-metastases either in the blood or body tissue. Cancer is thus both a regional and a systemic disease. To have an effective treatment against cancer one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics was thus founded to develop a new approach to treat both the big and the small aspects of the disease - in situ vaccination. Using our DfuseRxSM platform, we create novel formulations of proven drugs. Our products have high diffusion and dispersion properties in tumors. When injected directly into a tumor or visible metastases these products are able to kill the tumors and create sites for an adaptive immune response. The observed adaptive immune response further increases the efficacy of our system to destroy or regress the tumor, eliminate secondary tumors and micrometastases as well. The Company demonstrated that complete regression (CR) of large tumors in mice is possible using the technology. Animals that had a CR became fully resistant to re-inoculation of the same cancer.YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Lewis H. Bender
Chief Medical Officer: Ian B. Walters, MD
53 articles with Intensity Therapeutics, Inc.
-
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
6/3/2022
Intensity Therapeutics, Inc. announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with pembrolizumab in patients with relapsed, refractory and metastatic solid tumors, will be presented on June 5, at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago and virtually from June 3-7, 2022.
-
Four life sciences companies posted previews of their respective programs ahead of the American Society of Clinical Oncology (ASCO) annual meeting on June 5, 2022.
-
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas
6/2/2022
Intensity Therapeutics, Inc. announced that data from its ongoing phase 1/2 clinical trial in refractory patients demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented on June 5, at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago and virtually from June 3-7, 2022.
-
Intensity Therapeutics Announces New Clinical Data in Solid Tumors for its Lead Asset, INT230-6
5/3/2022
Intensity Therapeutics, Inc. today announced that phase 2 sarcoma data, phase 2 breast cancer data and phase 1/2 solid tumor data from its ongoing cohort studies of lead asset, INT230-6, will be presented in two oral and three poster sessions at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held live at McCormick Place in Chicago, IL, and online, from June 3-7, 2022.
-
Intensity Therapeutics to Participate in the 34th Annual Roth Conference
3/9/2022
Intensity Therapeutics, Inc. announced that Lewis H. Bender, President and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference in Orange County, CA on Tuesday, March 15, at 10:30 am PT.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
12/10/2021
Intensity Therapeutics, Inc. ("Intensity"), today reported safety, pharmacokinetic, biomarker and efficacy data using INT230-6, with and without pembrolizumab, in heavily pretreated refractory breast cancer patients as part of the Company's phase 1/2 study, IT-01.
-
The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
-
Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December
11/30/2021
Intensity Therapeutics, Inc. today announced that new breast cancer data from its phase 1/2 study IT-01 using novel lead asset, INT230-6, will be presented at the San Antonio Breast Cancer Symposium (SABCS) being held virtually and in-person at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 7-10, 2021.
-
Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at The Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
11/13/2021
Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced the Company made two presentations on novel lead asset, INT230-6, at the Society for Immunotherapy of Cancer's 36th Annual Meeting in Washington, D.C.
-
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the CTOS 2021 Virtual Meeting
11/12/2021
Intensity Therapeutics, Inc. announced that data from its open-label Phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in adult subjects with metastatic sarcomas, is being presented today, in an oral presentation, at the Connective Tissue Oncology Society Virtual Annual Meeting (CTOS).
-
Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November
11/3/2021
Intensity Therapeutics, Inc. today announced that data on the Company's novel lead asset, INT230-6, will be presented at the Connective Tissue Oncology Society Annual Meeting (CTOS) and the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC) in November.
-
Clinical Catch-Up: June 1-6
6/7/2021
With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news. -
Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors
6/2/2021
INT230-6 monotherapy overall showed an estimated 62% survival at one year, Patients receiving a dose of INT230-6 alone ≥50% of their tumor burden demonstrated a one-year survival estimate of 78%, Combined with pembrolizumab the one-year median overall survival estimate was 88%,
-
BioSpace continues to take a look at some of the data that will be shared at the 2021 ASCO meeting. Here are some of them.
-
Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
5/20/2021
Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Clinical Catch-Up: March 22-26
3/29/2021
There was a fair amount of clinical trial news last week. Here’s a look. -
Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer
3/24/2021
Intensity Therapeutics, Inc. (“Intensity”), a clinical-stage biotechnology company developing proprietary, intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced that following receipt of the authorization from Health Canada, Intensity executed agreements with The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized
-
Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411)
11/11/2020
Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced new efficacy and safety data from the ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate.
-
Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study
9/17/2020
Intensity Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of the cancer, today announced that the first patient has been dosed with a combination of INT230-6, the Company’s lead investigational product, and Yervoy® (ipilimumab), Bristol Myers Squibb’s (BMS) Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4)